Bleeding News and Research

RSS

Patient need to share medication side effects with health care team: Retired family doctor

"I had a wonderful gentleman patient who had resistant blood pressure," recalls Vicki Koenig, M.D., a retired family doctor in Exmore, VA. "When he came for a blood pressure check on the latest new med and it was great, I was ecstatic. Then he said, 'But I notice my urine's a little dark.' His was one of the first cases of fatal liver complications from this medication."

5 Feb 2011

Patients receiving cancer treatment may experience skin, hair, nail problems

A cancer diagnosis and subsequent treatment, which commonly includes chemotherapy or radiation, can be taxing physically and emotionally on any patient. If that is not enough, dermatologists are cautioning patients receiving cancer treatment and cancer survivors that they may experience a host of skin, hair or nail problems as a direct result of their therapy that may require additional treatment by a dermatologist.

5 Feb 2011

Practice proper sun protection to reduce risk of future skin cancers, warn dermatologists

For many young adults, the serious health consequences of tanning have been shown to have little impact on their behavior when it comes to sun exposure. But with spring break around the corner, dermatologists are urging people -- particularly young adults -- to practice proper sun protection and understand the importance of early detection of skin cancer, the most common type of cancer.

5 Feb 2011

First mobile application is now available for clinicians to diagnose bleeding disorders

Novo Nordisk announced today the availability of Coags Uncomplicated – the first mobile application to assist in the diagnosis of bleeding disorders – created in partnership with Craig Kessler, MD, Professor of Medicine and Pathology and Director of the Coagulation Laboratory, Georgetown University Hospital, Lombardi Comprehensive Cancer Center.

5 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

Miracle baby after radical new procedure for uterine fibroids

Amy Cordle is the first woman in Australia to become a mother after undergoing a radical new procedure. On Australia Day, the 31-year-old Albert Park woman’s little “miracle” arrived when daughter Neroli was born.

3 Feb 2011

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

In light of an aging population and increasing chronic vascular disease, there is a tremendous unmet need for new medical technologies to treat potentially dangerous chronic venous insufficiency (CVI) and blood clots, according to a Scientia Advisors review of the vascular device market released today. Both the CVI and the thrombosis segments present significant opportunities for medical device innovators.

3 Feb 2011

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Inspiration presents IB1001 PK data at European haemophilia congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Positive results from Factor IX-CTP comparative study in hemophilic mice

PROLOR Biotech, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX in Factor IX-depleted hemophilic mice.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

New state scorecard finds geographic disparities in health insurance coverage for children

Two years after the reauthorization and expansion of the Children's Health Insurance Program, a new Commonwealth Fund state-by-state scorecard evaluating how the health care system is working for children finds that federal and state action on behalf of children has helped preserve, and even expand, health coverage for this group, despite the severe recession.

2 Feb 2011

Study finds treatment-related mortality with bevacizumab in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab may be at an increased risk of treatment-related death when the drug is used in combination with other therapies.

2 Feb 2011

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating post-operative pain in hospitalized patients. A Phase III study published in the peer-reviewed journal Pain Practice concluded that IV ibuprofen significantly reduced both morphine use and self-reported pain intensity in patients recovering from abdominal hysterectomy compared to morphine alone.

27 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

An unrestricted grant from Octapharma USA supported the development of a Continuing Education (CE) initiative entitled the "The Diagnosis and Management of von Willebrand Disease," a program of the National Home Infusion Association (NHIA).

25 Jan 2011

SuppreMol completes successful pre-IND meeting with U.S. FDA

SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound SM101, which is being developed for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE).

24 Jan 2011

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.

24 Jan 2011

Researchers identify key player that lead to increased bleeding in diabetes patients with stroke injury

Strokes are a leading cause of mortality and adult disability. Those that involve intracerebral hemorrhage are especially deadly, and there are no effective treatments to control such bleeding. Moreover, diabetes and hyperglycemia are associated with increases in bleeding during hemorrhagic stroke and worse clinical outcomes.

24 Jan 2011

Bleeding News and Research

Patient need to share medication side effects with health care team: Retired family doctor

Patients receiving cancer treatment may experience skin, hair, nail problems

Practice proper sun protection to reduce risk of future skin cancers, warn dermatologists

First mobile application is now available for clinicians to diagnose bleeding disorders

CVT more common than previously thought, disproportionally affects pregnant women

Miracle baby after radical new procedure for uterine fibroids

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data at European haemophilia congress

Positive results from Factor IX-CTP comparative study in hemophilic mice

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

New state scorecard finds geographic disparities in health insurance coverage for children

Study finds treatment-related mortality with bevacizumab in cancer patients

Scientist identifies natural signaling molecule that can prevent Hemophilia A

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

SuppreMol completes successful pre-IND meeting with U.S. FDA

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

Researchers identify key player that lead to increased bleeding in diabetes patients with stroke injury

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News